GSK’s long-acting drug depemokimab hits goals of pivotal asthma studies
21 May 2024
Phase 3Clinical ResultImmunotherapy
GSK’s experimental drug depemokimab met the primary endpoint of a pair of Phase III studies in people with severe asthma, setting up marketing applications for the ultra-long-acting biologic. Kaivan Khavandi, the company’s global head of respiratory/immunology R&D, said the anti-IL-5 monoclonal antibody “could offer…a dosing schedule of just two injections per year.”
The SWIFT-1 and SWIFT-2 trials evaluated depemokimab versus placebo in adults and adolescents with severe asthma with type 2 inflammation characterised by blood eosinophil count. GSK noted that the studies hit their main goals of a reduction in the annualised rate of clinically significant exacerbations over 52 weeks.
Depemokimab, also known as GSK3511294, is also currently being evaluated in late-stage studies for eosinophilic granulomatosis with polyangiitis, chronic rhinosinusitis with nasal polyps and hypereosinophilic syndrome.
More to follow.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.